TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01125696
Drug: Zidovudine/lamivudine/lopinavir-ritonavir
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine/lamivudine/lopinavir-ritonavir given to mothers starting at 14-28 weeks gestation till labor/delivery and continued postpartum if maternal baseline CD4\<350
Study: NCT02858362
Drug: Ezutromid
Normalized name: Ezutromid
DrugBank: Ezutromid (DB12888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT02359097
Drug: Ferumoxytol
Normalized name: Ferumoxytol
DrugBank: Ferumoxytol (DB06215)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT02359097
Drug: Gadoteridol
Normalized name: Gadoteridol
DrugBank: Gadoteridol (DB00597)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00655200
Drug: insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study: NCT00470886
Drug: Telmisartan (Kinzal/Pritor, BAY68-9291)
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Primary care clinic hypertensive patients for whom physician decided to start the treatment with telmisartan
Study: NCT01155518
Drug: clomiphene
Normalized name: Clomiphene
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: thrice a week
Study: NCT03644472
Drug: nitrate rich beetroot juice
Normalized name: tamarind juice
DrugBank: Beet (DB10640)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This beverage contains 0.3 g of inorganic nitrate per 70 ml container, and is bottled and supplied by James White Drinks (UK).
Study: NCT03644472
Drug: nitrate depleted beetroot juice
Normalized name: tamarind juice
DrugBank: Beet (DB10640)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This beverage is identical in look and taste to the Beet-It organic shot, but has the nitrate removed. It is also bottled and supplied by James White Drinks (UK).
Study: NCT01336218
Drug: fostamatinib
Normalized name: FOSTAMATINIB
DrugBank: Fostamatinib (DB12010)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: oral tablets, 150mg (3 X 50mg) single dose per period
Study: NCT01336218
Drug: rifampicin
Normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral tablets, 600mg (2 X 300mg) 8 doses over 8 days
Study: NCT01280305
Drug: raloxifene
Normalized name: Raloxifene
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: raloxifene 60 mg bid
Study: NCT01891669
Drug: PF-06263507
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1 - PF-06263507 will be administered intravenously in 21-day cycles in cohorts of 2 or more patients starting at a dose of 0.05 mg/kg. Increases in dose will continue until MTD is determined.
Study: NCT01891669
Drug: PF-06263507
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 2 - Patients with select tumor types will be treated at the MTD or Recommended Phase 2 dose selected in Part 1.
Study: NCT01418365
Drug: Metronidazole + MMX Mesalazine/mesalamine placebo
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole 750 mg twice daily + MMX Mesalazine/mesalamine placebo once daily for 3 days orally, then Metronidazole 750 mg single dose + MMX Mesalazine/mesalamine placebo single dose on Day 4 orally
Study: NCT01418365
Drug: Metronidazole + MMX Mesalazine/mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole 750 mg twice daily + MMX Mesalazine/mesalamine 4.8 g once daily for 3 days orally, then Metronidazole 750 mg single dose + MMX Mesalazine/mesalamine 4.8 g single dose on Day 4 orally
Study: NCT00984646
Drug: Prevascar
Normalized name: Revascor
DrugBank: Rexlemestrocel-L (DB17606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal Prevascar, 5ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
Study: NCT00984646
Drug: Prevascar
Normalized name: Revascor
DrugBank: Rexlemestrocel-L (DB17606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal Prevascar, 50ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
Study: NCT00984646
Drug: Prevascar
Normalized name: Revascor
DrugBank: Rexlemestrocel-L (DB17606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal Prevascar, 250ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
Study: NCT00984646
Drug: Prevascar
Normalized name: Revascor
DrugBank: Rexlemestrocel-L (DB17606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal Prevascar, 1000ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
Study: NCT00984646
Drug: Prevascar
Normalized name: Revascor
DrugBank: Rexlemestrocel-L (DB17606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal Prevascar, 25ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
Study: NCT00984646
Drug: Prevascar
Normalized name: Revascor
DrugBank: Rexlemestrocel-L (DB17606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal Prevascar, 125ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
Study: NCT00984646
Drug: Prevascar
Normalized name: Revascor
DrugBank: Rexlemestrocel-L (DB17606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal Prevascar, 500ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
Study: NCT00984646
Drug: Prevascar
Normalized name: Revascor
DrugBank: Rexlemestrocel-L (DB17606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal Prevascar, 2000ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
Study: NCT02182726
Drug: MOBEC
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04347174
Drug: Suspension of heat killed (autoclaved) Mycobacterium w
Normalized name: Suspension of heat killed (autoclaved) Mycobacterium w
DrugBank: Mycobacterium w. Vaccine (DB15798)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomized to receive either Mycobacterium w in combination with standard care as per hospital practice or standard care alone in COVID-19 as per hospital practice.
Study: NCT00379691
Drug: phenylephrine
Normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00631943
Drug: Pregabalin (Lyrica)
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral pregabalin (Lyrica) capsules, initial dose of 75 mg twice daily, which could be increased to 300 mg twice daily at the discretion of the investigator. Patients were treated for up to 21 days.
Study: NCT03214666
Drug: GTB-3550 TriKE® Phase I
DrugBank: GTB-3550 (DB18494)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The 1st two patients will be assigned Dose Level 1. The study statistician will assign each new cohort of 2 patients to the most appropriate dose level based on updated toxicity probabilities.~* Dose Level 1 - 5 μg/kg/day~* Dose Level 2 - 10 μg/kg/day~* Dose Level 3 - 25 μg/kg/day~* Dose Level 4 - 50 μg/kg/day~* Dose Level 5 - 100 μg/kg/day~* Dose Level 6 - 150 μg/kg/day~* Dose Level 7 - 200 μg/kg/day
Study: NCT03214666
Drug: GTB-3550 TriKE® Phase II
DrugBank: GTB-3550 (DB18494)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive the maximum tolerated dose (MTD) established during Phase I with monitoring guidelines to stop the study early for excessive toxicity.
Study: NCT04038411
Drug: PD-1 Antibody, chidamide, lenalidomide and etoposide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PD-1 blocking antibody inhibits PD-1. Chidamide is an histone deacetylase inhibitor. Lenalidomide is a potent inhibitor of TNF-α. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA.
Study: NCT00150137
Drug: Methimazole
Normalized name: Methimazole
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01754805
Drug: peficitinib
Normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: oral
Study: NCT00761085
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard of care for pain management of acute episode of pain
Study: NCT00761085
Drug: Methadone
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Compare to standard of care for pain management of acute episode of pain
Study: NCT00470275
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03358524
Drug: Vitamin E 400 UNT
Normalized name: vitamin E 400 UNT
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin-E capsule (alpha tocopherol) 400 IU (once per day)
Study: NCT02474069
Drug: Secukinumab
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02296645
Drug: ChloraPrep
Normalized name: ChloraPrep
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Apply topically.
Study: NCT03656380
Drug: Mepolizumab 300 mg
DrugBank: Mepolizumab (DB06612)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Mepolizumab 300 mg subcutaneous injection
Study: NCT03656380
Drug: Mepolizumab 100 mg
Normalized name: mepolizumab 100 MG
DrugBank: Mepolizumab (DB06612)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Mepolizumab 100 mg subcutaneous injection
Study: NCT00528593
Drug: epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group 1 will receive Procrit once every three weeks, and group 2 will receive Procrit every week.
Study: NCT00526071
Drug: migalastat HCl
Normalized name: migalastat HCl
DrugBank: Migalastat (DB05018)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03286530
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients who fulfill eligibility criteria will be entered into the trial to receive Ruxolitinib.~After the screening procedures confirm participation in the research study. The participant will be given a drug diary. The participant will be asked to document information in the drug diary about the study treatment.
Study: NCT06245980
Drug: SGLT2 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: According to whether SGLT2i was used
Study: NCT02743104
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02743104
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02743104
Drug: midazolam and atropine
Normalized name: pralidoxime and atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02743104
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01551511
Drug: Tetrahydrocannabinol
Normalized name: Tetrahydrocannabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The add-on treatment consists of two phases: a step-up phase (day 1-5: 3 mg TID; day 6-10: 5 mg TID), and a stable dose phase (day 11-52: 8 mg TID). The dosage may be tapered to at least 5 mg TID, when 8 mg is not tolerated.
Study: NCT01995188
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 15 milligrams per kilogram (mg/kg) administered via IV infusion on Day 1 of each 21-day cycle until disease progression or death, whichever occurs first.
Study: NCT01995188
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin fixed dose of AUC=6 mg/mL\*min administered by IV infusion on Day 1 of each 21-day dose escalation and expansion cycles. Carboplatin will be administered for a maximum of 6 cycles or until disease progression or unacceptable toxicity, whichever is first.
Study: NCT02207452
Drug: Salbutamol
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol 5mg nebulised single dose
Study: NCT02207452
Drug: Ipratropium
Normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium 500mcg nebulised single dose
Study: NCT00071006
Drug: AG-013736 (Axitinib)
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients were treated with axitinib at starting dose of 5 mg BID continuous dosing.
Study: NCT02236936
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin total dose of \>200 mg administered weekly (40 mg/m2/week) or every three weeks (100 mg/m2 every three weeks) according to local standard; not given in combination with cetuximab
Study: NCT02305810
Drug: Everolimus 10 mg daily
Normalized name: everolimus 10 MG
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: everolimus is a recently approved mTOR inhibitor in advanced progressing well/moderately differentiated pancreatic neuroendocrine tumors
Study: NCT02114073
Drug: Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In study arm, ophthalmic emulsion of cyclosporine A 2% will be prescribed in postoperative phase.
Study: NCT02114073
Drug: Betamethasone
Normalized name: Betamethasone
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In control arm, betamethasone eye drop will be prescribed in postoperative period.
Study: NCT03417154
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3mg/kg IV (or if prior alloHSCT, 1 mg/kg) over 30 minutes every 14 days on Days 1 and 15 for up to four 28-day courses.
Study: NCT00995800
Drug: Fluticasone propionate / Formoterol fumarate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2 dose strength vs. placebo
Study: NCT05637580
Drug: Timing of drug administration
Normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The effect of drug administration timing on tumor and lymph node responses was observed.
Study: NCT02404779
Drug: cisatracurium besilate
Normalized name: Cisatracurium besilate
DrugBank: Cisatracurium (DB00565)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01145976
Drug: Cy-ATG
Normalized name: equine ATG
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydration with 0.45% NaCl at 6 liters/24 hours will be started on day -5. Cy 50 mg/kg in D5W 200 ml i.v. over 1-2 hours on days -5 to -2 by pump through a central venous catheter.~Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2
Study: NCT01145976
Drug: Flu-ATG
Normalized name: equine ATG
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine 30 mg/m2 will be infused intravenously over 30 minutes in D5W 100 ml for 6 consecutive days (days -7 to -2) Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2
Study: NCT00135499
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m², D1, 4 cycles
Study: NCT00135499
Drug: Vindesine
Normalized name: vindesine
DrugBank: Vindesine (DB00309)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/m², D1, D5, 4 cycles
Study: NCT00135499
Drug: Bleomycin
Normalized name: Bleomycin
DrugBank: Bleomycin (DB00290)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg, D1, D5, 4 cycles
Study: NCT00135499
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg, D1-D5, 4 cycles
Study: NCT00135499
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg, D1-D5, 4 cycles
Study: NCT02396459
Drug: Triac
Normalized name: TRIAC
DrugBank: Nitrilotriacetic acid (DB03040)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triac, individually titrated dose
Study: NCT00135499
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.4 mg/m², D1, 4 cycles
Study: NCT03836261
Drug: Acalabrutinib
Normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Acalabrutinib,
Study: NCT03836261
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Venetoclax
Study: NCT00749853
Drug: follicle stimulating hormone
Normalized name: follicle stimulating hormone
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pituitary down-regulation will be achieved using buserelin (Suprefact®, Hoechst, Frankfurt, Germany) at a fixed daily dose of 200 mg s.c., according to a long agonist protocol, starting on day 2 of the normal menstrual cycle. Treatment with r-hFSH (Gonal-F®, Serono Austria GmbH, Vienna, Austria) will be started in women with serum E2 concentrations \<200 pmol/l and no follicles \>15 mm in diameter or ovarian cysts on ultrasonographic examination. The initial r-hFSH dose will be 250 IU s.c. daily for 5 days, after which the dose will be increased to a maximum of 450 IU per day using a step-up protocol with steps of 50 IU/day.
Study: NCT00749853
Drug: follicle stimulating hormone
Normalized name: follicle stimulating hormone
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: No pituitary down-regulation will be performed. Treatment with r-hFSH (Gonal-F®, Serono Austria GmbH, Vienna, Austria) will be started in women with serum E2 concentrations \<200 pmol/l and no follicles \>15 mm in diameter or ovarian cysts on ultrasonographic examination. The r-hFSH dose will be 150 IU s.c. daily for 11 consecutive days.
Study: NCT03836261
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab
Study: NCT01039883
Drug: Albaconazole tablet 400mg
Normalized name: fluconazole Oral Tablet
DrugBank: Albaconazole (DB12073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albaconazole tablet 400mg single dose, then four albaconazole capsule 100mg single dose
Study: NCT01039883
Drug: Albaconazole 100mg capsules, then albaconazole 400mg tablet
DrugBank: Albaconazole (DB12073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four albaconazole capsule 100mg single dose, then albaconazole tablet 400mg single dose
Study: NCT00464191
Drug: escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04506138
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab 200mg D1, D22
Study: NCT04506138
Drug: Paclitaxel for Injection (Albumin Bound)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel for Injection (Albumin Bound) 100mg/m\^2 D1, D8, D22, D29
Study: NCT04506138
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC5 D1, D22
Study: NCT02162199
Drug: Debio 1450
Normalized name: DEBIO-1347
DrugBank: DEBIO-1347 (DB12903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single sentinel dosing of 40 mg per unit capsules is planned to escalate from 80 mg to 160, 320, 480, 640 and 800 mg, per respective dosing group. Doses may be modified based on review of available safety and pharmacokinetic (PK) data.
Study: NCT02223494
Drug: Terbogrel
Normalized name: Terbogrel
DrugBank: Terbogrel (DB12204)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00003266
Drug: methylphenidate hydrochloride
Normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01566747
Drug: Pazopanib
Normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pazopanib 800mg day to be given continuously until disease progression.
Study: NCT03818334
Drug: ATG
Normalized name: eATG
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihuman T-Lymphocyte Immune Globulin 25 mg/flask
Study: NCT02630992
Drug: Amoxicillin-Clavulanate potassium
Normalized name: amoxicillin / clavulanate
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01209533
Drug: Iloprost
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled iloprost 2.5 or 5 micrograms four times daily for 14 days
Study: NCT04421027
Drug: Baricitinib
Normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given orally
Study: NCT00427765
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Test Dose = 32 mg/m\^2 IV for 1 Day; 130 mg/m\^2 IV for 4 Days
Study: NCT00427765
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 70 mg/m\^2 IV for 2 Days
Study: NCT00169065
Drug: Clozapine
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00169065
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00387985
Drug: MOA-728
Normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00590772
Drug: montelukast
Normalized name: Montelukast
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg po each day (compared to placebo for 2 weeks)
Study: NCT03284307
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 participants will be administered Dexmedetomidine.
Study: NCT03284307
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 participants will be administered Ketamine.
Study: NCT03284307
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 participants will be administered Propofol.